Artificial intelligence can augment and assist human-driven processes and skills while machine learning drives strategy and decision-making, but people remain responsible for how that
information is harnessed. Our strength is based on this premise and the relentless pursuit to help our collaborators excel in achieving their goal to be at the forefront of innovation excellence.
AlphaMeld® – Anticipating the Future with an Innovation Monitoring System
AlphaMeld® is a universal signal detection system created on the premise that every innovation begins with a core discovery or invention that gathers momentum. Powered by artificial intelligence and machine learning algorithms, the platform operates in real-time and eliminates dependence on a time-series. Patterns of breakthrough innovation are monitored and discrete connections made from petabytes of data. The platform provides a first mover advantage to access innovation.
We’ve spent over a decade creating data sets (multiple data types, internal and externally sourced, structured, and unstructured) that are cleaned, curated, and connected for use in our suite of products. The platform is actively learning with hundreds of industry-specific algorithms that use these vast repositories of data to uncover hidden connections and make associations. Analytics are presented to our world-class scientists, researchers, and data scientists for rapid judgment and to further improve and accelerate every step of the innovation process.
We have created a suite of AlphaMeld-powered products that are trained to amplify human expertise to enable robust decision-making tailored to the needs of multiple stakeholders within an organization. With AlphaMeld®, shaping and driving innovation has never been easier – whether it’s accelerating new product development, optimizing product portfolios, or propelling breakthrough innovations, we strive to provide a personalized solution for our customers’ requirements.
AlphaMeld® powers a suite of products custom-built for the pharmaceutical and biopharmaceutical industries to stay ahead of the innovation curve. Artificial Intelligence and disease-specific algorithms amplify human expertise to address high-value questions, accelerating robust decision making for stakeholders in portfolio strategy, R&D, BD&L, clinical operations, and competitive/business intelligence.
Rapidly access AI- and ML-validated associations between the most relevant emerging targets and technologies and a disease indication. EIMeldTM addresses the biological complexity involved in drug development by using a systems-based approach. Optimal target-disease combinations are derived with supporting strength and quality of evidence. Also taken into account are profound connections between novel targets, genes, pathways, and drugs in the context of a disease indication.
Rapidly access AI- and ML-validated associations between the most relevant emerging targets and a therapeutic indication. TargetMeld™ addresses the biological complexity involved in drug development by using a systems-based approach. Optimal target-therapy combinations are derived with supporting strength and quality of evidence. Also taken into account are profound connections between novel targets, genes, pathways, and disease in the context of a therapeutic indication.
Gain a first-mover advantage to identify assets with a high probability of clinical success to focus and prioritize efforts on high-value assets. RxMeldTM identifies the spectrum of clinical assets (early to late-stage and marketed) in a disease indication for all major therapeutic areas and prioritizes based on the probability of success to support clinical development initiatives.
Gain a competitive and business advantage by leveraging signal triangulation for multiple data sets. CIMeldTM enables AI- and ML-driven insights to identify threats and opportunities for a portfolio based on disease indication, drug, gene, target, or therapeutic indication.
CliniMeldTM utilizes the transformative power of AI and ML to enhance the clinical trial planning and execution process.
VetMeldTM provides unprecedented access to disruptive innovation across the value chain to enhance the productivity of key stakeholders. VetMeldTM ensures the cross applications of human therapeutics to animal therapeutics are fully mapped and exploited to design the most cutting edge treatment options for farm and pet animals.
VaxMeldTM derives associations and insights between pathogens and a host response. VaxMeldTM identifies novel antigenic targets and creates immunological fingerprinting for the generation of efficacious vaccines.